Market research
RNXT RenovoRx Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- 7.125
- Dividend yield
- Not available
- Beta
- 1.12
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US75989R1077
- Market cap
- 78M
- P/E ratio
- Not available
- Analyst target
- 7.125
- Dividend yield
- Not available
- Beta
- 1.12
About
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the RNXT discussion.
No comments yet
Start a focused discussion about RNXT.